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pression with versus without sleep difficulties was associated with lower utility
scores (b-0.04, p0.001), greater work impairment (rate ratio1.4, p0.001), activ-
ity impairment (rate ratio1.30, p0.001), andmore healthcare provider visits (rate
ratio1.31, p0.001). CONCLUSIONS: Sleep difficulties, when combined with de-
pression, are associated with lower quality of life and greater work productivity
loss and health resource use than either sleep difficulties or depression alone, or
neither. Greater attention to sleep problems in depression may lead to better
outcomes.
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COMPARISON OF DIFFERENT COMORBIDITY MEASURES FOR PREDICTING
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OBJECTIVES: Comorbidity risk adjustment methods are increasingly used to re-
duce potential confounding in epidemiological research.We sought to compare the
performances of four comorbidity measures in predicting physical and mental
health among patients with dementia. METHODS: Nationally representative data
from the 2000-2003 Medical Expenditure Panel Survey (MEPS) were used. The Elix-
hauser and the Charlson/D’Hoore, methods were based on the International Clas-
sification of Disease, 9th Revision, Clinical Modification (ICD-9-CM) codes whereas
the Chronic Disease Score (CDS)-1 and the CDS-2 were based on prescription med-
ications. The performances were compared using the R2 obtained from linear re-
gression models. The outcomes of interest were scores on the Medical Outcomes
Short Form-12 (SF-12) Physical Component Scale (PCS) and Mental Component
Scale (MCS). RESULTS: In linear regression models controlling for age and gender
the CDS-2 performed the best (R2 0.242 for PCS, R2 0.157 forMCS) followed by the
Elixhauser (R20.238 for PCS; R20.107 for MCS), the Charlson/D’Hoore (R20.160
for PCS; R20.038 for MCS)and the CDS-1 (R20.154 for PCS; R20.025 for MCS).
Combining the ICD-9-CM based (Elixhauser) measure with the medication based
(CDS-II) measure improved the R2 for both PCS (R2 0.357) and MCS (R20.250).
CONCLUSIONS:We found that CDS-II comorbidity measurement method outper-
forms Elixhauser, Charlson/D’Hoore and CDS-I methods in predicting physical and
mental health in dementia patients studied. Best performance, howver, was ob-
served in themodel that combined diagnoses based (Elixhauser) measure with the
medication based (CDS-II) measure.
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OBJECTIVES: This study examined the burden of depression on employees using
measures ofwork productivity.METHODS: Individuals (18 years of age) employed
full-time with diagnosed depression completed a Web-based computer-generated
25-minute survey in February 2010 (study population identified by Harris Interac-
tive™). The survey used the Patient Health Questionnaire (PHQ-9) to assess depres-
sive symptoms, and the Health and Work Performance Questionnaire (HPQ) and
Work Productivity and Activity Impairment (WPAI) questionnaire to assess absen-
teeism and presenteeism. Higher scores represent more work missed on the HPQ
(hours monthly) and WPAI (% time weekly) absenteeism scales. Higher scores on
the HPQ presenteeism scale (measure of actual performance to possible perfor-
mance, 0-100 scale), and lower scores on the WPAI presenteeism scale (% impair-
ment past 7 days), represent better performance. Work productivity was assessed
by depression severity using a trend test based on an analysis of covariance with
age, gender and PHQ-9 score as independent variables. RESULTS: A total of 1051
full-time employees were evaluated (58% female, mean age 47 yrs). PHQ-9 scores
indicated 423 (40.25%) employees with no depression symptoms, 319 (30.35%) with
mild, 166 (15.79%)withmoderate, 82 (7.80%)withmoderately severe, and 61 (5.80%)
with severe depression. All levels of depression were associated with decreased
work productivity. Both the HPQ (presenteeism [81.04, 73.54, 68.61, 66.10, 61.48, no
depression, mild, moderate, moderately severe, and severe depression groups, re-
spectively], p0.0001) andWPAI (absenteeism [0.92, 3.04, 4.55, 7.43, 14.00] and pre-
senteeism [10.67, 26.17, 38.81, 44.68, 54.31], p0.0001) showed progressive worsen-
ing of work productivity with increasing severity of depression. Pearson’s
coefficient of correlation for WPAI with PHQ-9 was 0.3158 for absenteeism and
0.6055 for presenteeism (p0.0001). CONCLUSIONS: Depression has a significant
impact on work productivity asmeasured by theWPAI and HPQ. Presenteeism and
absenteeism worsened with increasing depression severity, and decreased overall
productivity was seen at all levels of depression severity.
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NEW DISEASE MANAGEMENT PROGRAM FOR OPIOID DEPENDENT PATIENTS
DECREASES DRUG USE AND INCREASES 12 STEP MEETING ATTENDANCE: ONE
YEAR RESULTS OF A RANDOMIZED CLINICAL TRIAL
Tkacz J, Ruetsch C
Health Analytics, LLC, Columbia, MD, USA
OBJECTIVES: Buprenorphine-medication assisted treatment (B-MAT) is clinically
effective for opioid dependence (OD). Ancillary treatment services, however, may
be needed tomaximize treatment efficacy. The purpose of the present studywas to
investigate the one year effect of a disease management program on treatment
outcomes among a national sample of OD patients.METHODS: Opioid dependent
patients new to B-MAT (N1.426) were randomized to receive either B-MAT plus a
patient support program (intervention group, n  987) or B-MAT alone (standard
care group, n  439). The intervention was a confidential, outbound, telephonic
support program designed to provide new B-MAT patients encouragement and
help them resolve problems inherent to early B-MAT treatment. Once enrolled in
the study, all patients completed the Addiction Severity Index (ASI) and Treatment
Services Review (TSR) at various time points over one year. The ASI is a semi
structured interview designed to measure problem severity in seven functional
areas known to be affected by alcohol and drug dependence. The TSR assess utili-
zation of a variety of health, social, legal, employment, and family support services.
RESULTS: Logistic regression analyses controlling for baseline problem severity
and demographics revealed that intervention group subjectswere significantly less
likely to abuse opioids at month 12 (p  .05; exp ()  1.50), and were significantly
more likely to attend 12 step/self-help groupmeetings for substance abuse (p .05;
exp ()  0.71) compared to the standard care group. CONCLUSIONS: Randomiza-
tion to the diseasemanagement program resulted in a decrease in the reported use
of opioids and an increase in self-help group counseling attendance. Supplement-
ing B-MAT with a structured disease management program seems to be an effec-
tive way to improve patient outcomes. Current results replicate, and extend to
B-MAT, findings from other studies of the effect of telephonic intervention pro-
grams on patient outcomes.
PMH59
DIFFERENCES IN BASELINE PROBLEM SEVERITY BETWEEN PRESCRIPTION AND
STREET OPIOID ABUSERS AMELIORATED AFTER PARTICIPATION IN DISEASE
MANAGEMENT PROGRAM: RESULTS AT ONE YEAR
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OBJECTIVES: Opioid dependence (OD) results from the continued abuse of opioids,
which includes prescribed medication for pain (i.e., hyrodcodiene, oxycontin) and
“street” opioids including heroin and methadone. Although patients receive the
same OD diagnosis regardless of their opioid of abuse, prescription and “street”
users represent two distinct patient populations, each with their own unique co-
morbidities and psychosocial profiles. The purpose of this study was to compare
the effectiveness of a new diseasemanagement program (DMP) among the various
types of OD patients. METHODS: A national sample of OD patients new to bu-
prenorphine-medication assisted treatment (B-MAT) were enrolled in the study.
The DMP was a confidential, outbound, telephonic support program designed to
provide new B-MAT patients encouragement and help them resolve problems in-
herent to early B-MAT treatment. All patients completed the Addiction Severity
Index at various time points over the course of the year. Patients were classified
into prescription users (n  303) and street users (heroin or methadone; n  103)
based on their reported opioid of abuse. RESULTS: Street users had significantly
higher baseline legal composite scores (0.13 vs. 0.05; p  0.001), while prescription
users had significantly higher baseline medical (0.31 vs. 0.18; p  0.001) and drug
(0.27 vs. 0.25; p 0.05) composite scores. Within-subjects tests revealed significant
decreases on all three composite scores by month twelve. Additionally, group dif-
ferences on the three composite scores were ameliorated by month twelve (p’s 
.10). CONCLUSIONS: OD patients have a diverse range of medical, social, and sub-
stance abuse histories,making the design of anyDMP for this population especially
complicated. Although patients in this study evidenced two conflicting problem
sets, results showed that the DMP worked equally in ameliorating the challenges
faced by each group, indicating good generalizability of this particular DMP.
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OBJECTIVES:WAVE-bd (WideAmbispectiVE study of the clinicalmanagement and
burden of bipolar disorder [BD]) is ongoing to address limitations of longitudinal BD
studies to-date, few of which investigate caregiver burden. Objectives are to pro-
vide reliable, real-world data, including assessment of burden among caregivers
(usually unpaid relatives or friends), an important consideration in BD patient
management.METHODS:Multinational, multicentre, non-interventional, longitu-
dinal study of patients diagnosed with BD with1 mood event in the preceding 12
months (retrospective data collection from index mood event to enrollment, fol-
lowed by a minimum 9months’ prospective follow-up). Patient selection provided
a representative sample of BD populations in daily practice. Caregiver burden was
assessed using the BurdenAssessment Scale (BAS), where scores range 19–76, with
higher scores indicating greater burden. Assessment was carried out once during
any part of the prospective follow-up for one caregiver only per patient. RESULTS:
To-date, 583/2880 patients (BD-I: 21.8%; BD-II: 16.8%) have attended their baseline
appointment with their primary caregiver (caregiver mean age 50.2 years; 57%
female). The majority of caregivers were patients’ partners or parents (44.1% and
33.5%, respectively), with 10 years of education. The professional status of care-
givers was: employed (47.4%), retired (22.7%), homemaker (16.6%), unemployed
(5.8%) and other (7.4%). BAS scores were collected from 574 caregivers, and total
caregiver burden was 47.6  13.7 (n424) for BD-I and 42.4  12.6 (n150) for BD-II
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(p0.0003). Burden was recorded among caregivers of patients with (at inclusion)
euthymia (43.8  13.1; n329), mania (47.7  13.6; n41), hypomania (51.6  12.7;
n44), depression (49.9  14.4; n137), or mixed disease status (50.2  9.5; n20).
CONCLUSIONS: This ongoing study provides multinational perspectives on the
high burden experienced by caregivers of individuals with BD-I and BD-II in every-
day clinical practice settings. Study funded byAstraZeneca; Clinical Trials Registry:
NCT01062607.
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OBJECTIVES: As data is limited, to determine national estimates and characteris-
tics of Alzheimer’s disease and senile dementia (ADSD) visits in the United States
(US) ambulatory setting. METHODS: Through a retrospective analysis of the 10-
year (1998-2007) physician-office visit data of National Ambulatory Medical Care
Survey, we calculated weighted national estimates and percentages of ADSD
visits made by patients aged 40 years and older with relevant ICD-9CM codes
(290.xx, 294.xx, 331.xx). In multivariate logistic regression we analyzed the charac-
teristics associated with anti-dementia drug mention at ADSD visits. RESULTS:
Of an estimated 6.5million adult ambulatory care visits (5 visits per 1000 people) for
ADSD, 52%, 25%, 20%, 14%, and 11%, mentioned an antidementia (memantine,
cholinesterase inhibitor, or donepezil/rivastigmine/gallantamine), anticholinergic,
antidepressant, antipsychotic, and antianxiety drug respectively. Patients with
ADSD visits were predominantly 75-84 year olds (53%), white (89%), female (63%),
living in metropolitan statistical area (81%), South (30%) and Northeast (28%), on
Medicare (73%), seeing a freestanding private practice physician (61%) or a neurol-
ogist (32%), established patient (88%), and reported hypertension (12%). In multi-
variate analyses controlling for gender, type of dementia, comorbidity, and visit-
year, any versus no anti-dementia drug mention was significantly less likely at
visits by other versus white-race patients (adjusted odds ratio [OR] is 0.44,95%CI:
0.42-0.46), new versus established patients (OR0.38;95%CI:0.37–0.39), by those on
self-pay versus private-insurance (OR0.63;95%CI:0.56–0.70), and in South
(OR0.43;95%CI:0.41–0.44) and West (OR0.41;95%CI:0.40–0.43) versus those in
Northeast (all P 0.0001). CONCLUSIONS: About 50% and 25% of ADSD visits
mentioned an anti-dementia drug and other drugs, respectively. New patients,
those of other races, on self-pay and living in South or West of the US were less
likely to receive an anti-dementia drug. Study findings’ suggest deficiencies in
access and quality of dementia care in the USwarranting the attention of providers
and payers and need further study.
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INTRODUCTION Although benzodiazepines are primarily considered anxiolytics,
some have other indications such as seizures, insomnia, alcohol withdrawal, and
tardive dyskinesia. They are also commonly abused medications, especially the
brandnameproducts, alone and in combinationwith other drugs (e.g.methadone).
They are classified, on the basis of their half lives, into short-, intermediate- and
long-acting agents. The side effects of falling and fractures cause benzodiazepines
to be unattractive for elderly patients. OBJECTIVES: To describe trends in the uti-
lization of, spending on, and average per-prescription spending on benzodiaz-
epines, individually, stratified by half life, and overall, for the U.S. Medicaid pro-
grams over the past two decades.METHODS: A retrospective, descriptive analysis
was performed using the national Medicaid pharmacy claims database, which has
information on outpatient prescription claims. Quarterly prescription counts and
reimbursement amountswere calculated for each of the benzodiazepines (branded
or generic) reimbursed by Medicaid. Average per-prescription spending was found
by dividing reimbursement by the number of prescriptions. RESULTS: Prescrip-
tions for benzodiazepines among Medicaid beneficiaries increased from 6.15 mil-
lion in 1991 to 16.70 million in 2009. Expenditures rose from $108.75 million to
$165.79 million over the same time period, implying an average per-prescription
price of approximately $10 in 2009. Whereas utilization of long-acting agents re-
mained relatively constant at 1.79 million prescriptions per year, prescriptions for
short-acting and intermediate-acting drugs rose from 1.74 million to 4.94 million,
and from 2.82 million to 9.91 million, respectively. Prescriptions for flurazepam
have fallen steadily from 439,106 in 1991 to 45,754 in 2009. CONCLUSIONS: Spend-
ing on benzodiazepines represents  1% of Medicaid’s spending on outpatient
drugs. Moreover, due to generic entry for some of the drugs, the percentage rise in
spending on benzodiazepines since 1991 (52.5%) was less than the general rate of
inflation (57.5%). By its policy of reimbursing for generic, rather than branded,
prescriptions, Medicaid reduces the opportunity for abuse.
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OBJECTIVES: The U.S. Food and Drug Administration’s decision to mandate a black-
boxwarning on antidepressants indicating that they are associatedwith an increased
risk of suicidal behavior in children and young adults remains controversial. We
aimed to quantify the tradeoffs of alternative strategies in treating pediatric major
depressive disorder (MDD) with respect to clinical benefit and risk of fatal and non-
fatal suicidal behavior over a five-year time horizon. METHODS: We developed a
disease simulationmodel integrating epidemiological and clinical data from the pub-
lished literature in order to simulate the effect of three treatment strategies (i.e., Se-
lective serotonin reuptake inhibitors (SSRIs), cognitive behavioral therapy (CBT), and a
combination of SSRIs andCBT) on aU.S. population of children and young adultswith
MDD. We explored the implications of different scenarios of data extrapolation be-
yond the time horizon of existing data and of uncertain assumptions about suicide
attempt risks and patients’ response to treatment. Main outcome measures were
symptom-free weeks, suicide attempts, and suicide deaths. RESULTS: In a cohort of
1,000,000 simulated children and young adults, there were more than twice as many
suicide deaths among those started on SSRIs (1291), compared to those started onCBT
(506) or combination treatment (621) over the first 36 weeks of treatment. Over a
five-year time horizon, this hierarchy of suicide risk persisted, even under assump-
tions most favorable to SSRIs. With respect to symptom-free weeks, combination
treatmentwas superior to both SSRIs and CBT alone, but this differencewasmarginal
over a five-year time horizon. CONCLUSIONS: Considering the risk-benefit profile
over a five-year period, CBT appears to offer a safer profile with respect to suicide
deaths and attempts than combination treatment or SSRIs alone. While combination
treatment maximizes symptom-free weeks, the additional benefit over the five-year
time horizon is modest and must be weighed against the clinically meaningful in-
crease in fatal suicides.
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COMPARISON OF THE RISPERIDONE EQUIVALENT DOSES FOR THE 9 MOST
FREQUENT TYPICAL AND ATYPICAL ANTIPSYCHOTICS IN PATIENTS
DIAGNOSED WITH SCHIZOPHRENIA BASED ON PRODUCT LABELS WITH
ACTUAL DOSAGES PRESCRIBED IN A LARGE NATIONAL DATABASE
Parente AK, Wang RH, Jones BT
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OBJECTIVES: Physicians often make dosage decisions based on experience and
heuristic factors in addition to the product label. This makes it difficult for econo-
mists to compare the “real world” costs and benefits of alternative therapeutic
choices. We compare a published methodology for calculating therapeutic dose
equivalence based on approved labeling for varous antipsychotics prescribed for
schizophrenia with actual prescription data in that population. METHODS: The
sample consisted of a proportional selection of patients that derived from a popu-
lation of patients of all ages, across all payers, and in all regions of the United
States. The information included NDC code sets, quantity, and day of supply and
was aggregated from pharmaceutical prescriptions files. The frequency distribu-
tion measured the top antipsychotic medications in patients diagnosed with
schizophrenia. The therapeutic dose equivalence was determined using themeth-
odology of Woods (2003) as the comparator. RESULTS: A total of 324,724 patients
with a diagnosis of schizophrenia were included in the study. Doses equivalent to
1mg/day of Risperidonewere 86.17mg/day of Quetiapine, 5.09mg/day of Olanzap-
ine, 5.25 mg/day of Aripiprazole, 92.28 mg/day of Clozapine, and 33.74 mg/day of
Ziprasidone. CONCLUSIONS:With the ever-increasing array of differntially-dosed
medications available, it is imperative for physicians and outcomes researchers to
utilize estimation of therapeutic dose equivalence that reflects actual practice pat-
terns so that informed decisions can be made evaluating the cost and cost-effec-
tiveness of various therapeutic choice. Our study enables pharmacoeconomic
comparisons among antispychotics not only according to label-approved dosages,
but also real-world dosing patterns.
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EFFECT OF PRESCRIPTION MONITORING PROGRAMS (PMP’S) ON OPIOID
OVERDOSE ADMISSION
Painter JT
University of Kentucky, Lexington, KY, USA
OBJECTIVES: Over the past three decades the concept of prescription monitoring
programs (PMPs) has developed immensely, however little evidence regarding
their effectiveness has been collected. This study focuses on simple difference-in-
difference evaluations, comparing the implementation effect of a PMP in Tennes-
see with Kentucky, which has a well-established PMP, andMissouri, which has not
to-date enacted legislation to develop a PMP. The effect of interest is opioid over-
dose hospital admission.METHODS: The present study examines a simple differ-
ence-in-difference model of a natural experiment caused by the staggered imple-
mentation of prescription monitoring programs in Kentucky, Missouri, and
Tennessee. We implement a pre-post design with the primary outcome of interest
being hospital admission due to opioid overdose. For this evaluation we use all
claims from Kentucky, Missouri, and Tennessee in the HCUP-NIS data from 2006
and 2008. The data is separated according to whether the hospital admission was
due to opioid overdose. Four models are examined: main effects, individual fixed
effects, and the full model, which takes into account both year and state fixed
effects and shows the true effect of the Tennessee implementation. Although the
findings in the Tennesseemodels trend positively, there are no significant findings
in the full model. RESULTS:We look at various models, including fixed effects for
state and year, but no consistently significant effect is seen. Despite no statistically
significant findings, coefficients do trend in expected directions suggesting a sound
model. CONCLUSIONS: There are multiple possible reasons for the lack of signifi-
cant findings, including several study limitations. Despite the limitations, it can be
said that the Controlled Substance Abuse Database Program in Tennessee has no
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